ACOT7: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: ACOT7

NCBI ID: G11332

ACOT7

ACOT7: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Acetyl-CoA Transferase IIa (ACOT7) is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle, which is a central metabolic pathway that generates energy in the form of ATP from food molecules. The ACOT7 gene has been identified as a potential drug target (or biomarker) for several diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

Diseases associated with ACOT7

Several studies have identified ACOT7 as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

1. Cancer

Studies have shown that ACOT7 is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. In addition, ACOT7 has been shown to promote the growth and metastasis of cancer cells. Therefore, ACOT7 has been identified as a potential drug target for cancer treatment.

2. Neurodegenerative diseases

ACOT7 has been shown to be involved in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroglial plaques.

3. Metabolic disorders

ACOT7 is also involved in the metabolism of several nutrients, including calcium, phosphorus, and magnesium. The ACOT7 enzyme has been shown to regulate the levels of these minerals in the body, which can lead to disorders such as hypocalcemia (low calcium levels) and hypomagnesaemia (low magnesium levels).

ACOT7 as a drug target

ACOT7 has been identified as a potential drug target due to its involvement in the citric acid cycle and its role in the development and progression of several diseases. The ACOT7 enzyme has been shown to be involved in the production of reactive oxygen species (ROS), which can damage cellular components and contribute to the development of oxidative stress-induced diseases.

In addition, ACOT7 has been shown to promote the growth and survival of cancer cells, which makes it an attractive target for cancer treatment. Several studies have shown that inhibiting ACOT7 can lead to the regression of cancer tumors in animal models.

Anti-ACOT7 drugs

Several anti-ACOT7 drugs have been developed as potential treatments for various diseases. These drugs work by inhibiting the activity of ACOT7 or by inhibiting the formation of ROS, which can reduce the damage caused by ROS in cells.

1. inhibitors of ACOT7

Several inhibitors of ACOT7 have been developed, including benzotiazole, a class of inhibitors of G-protein-coupled receptors (GPCRs), and 2-phenyl-1-propanone (2-PP), a metabolite of acetyl-CoA. These inhibitors have been shown to reduce the production of ROS and to inhibit the growth and metastasis of cancer cells.

2. Antibiotics

Several antibiotics have been developed as potential treatments for neurodegenerative diseases, including bacteria that are naturally occurring in the body, such as Mycobacterium tuberculosis. These antibiotics have been shown to reduce the production of ROS and to inhibit the growth of cancer cells.

Conclusion

ACOT7 is a protein that is involved in the citric acid cycle and has been identified as a potential drug target for several diseases, including cancer, neurodegenerative diseases, and metabolic disorders. The ACOT7 enzyme has been shown to promote the growth and metastasis of cancer cells and to contribute to the development and progression of these diseases. In addition, ACOT7 has

Protein Name: Acyl-CoA Thioesterase 7

Functions: Catalyzes the hydrolysis of acyl-CoAs into free fatty acids and coenzyme A (CoASH), regulating their respective intracellular levels (PubMed:10578051). Preferentially hydrolyzes palmitoyl-CoA, but has a broad specificity acting on other fatty acyl-CoAs with chain-lengths of C8-C18 (PubMed:10578051). May play an important physiological function in brain (PubMed:10578051)

The "ACOT7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACOT7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets